<DOC>
	<DOCNO>NCT00104286</DOCNO>
	<brief_summary>This phase I , single-arm , open-label , single-center study establish recommend infusion schedule Troxatyl™ administer continuous infusion 2-5 day subject solid tumor .</brief_summary>
	<brief_title>Study Troxatyl™ Administered Continuous Infusion Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Troxacitabine</mesh_term>
	<criteria>Diagnosis advance solid malignancy refractory prior therapy unlikely benefit know therapy ( e.g. , chemotherapy , radiation therapy , surgery ) . Diagnosis confirm histologically cytologically . Subjects may receive prior cancer therapy ( include surgery , radiotherapy , chemotherapy , hormonal therapy ) , must complete therapy least 30 day prior study drug administration ( 42 day nitrosourea mitomycin ) . Subjects must recover toxic effect associate prior treatment . Subjects must Eastern Cooperative Oncology Group performance status ≤ 2 estimate life expectancy least 12 week . Subjects must adequate organ immune function indicate standard laboratory test . The subject must understand , able , willing , likely fully comply study procedure , include schedule followup , restriction . The subject must give write , personally sign date , informed consent participate study implement study related procedure . Previously document brain metastasis . Active uncontrolled infection . Subjects uncontrolled medical problem , unrelated malignancy , sufficient severity opinion investigator , impair ability give inform consent unacceptably reduce safety propose treatment . Neurological psychiatric disorder would interfere consent study followup . Prior treatment 6 course alkylating agentcontaining chemotherapy ( except lowdose cisplatin ) 4 course carboplatin , radiation therapy &gt; 25 % hematopoietic reserve two course mitomycin C nitrosourea . Known suspected intolerance hypersensitivity study material [ closely related compound ] state ingredient . History alcohol substance abuse within last year . Use another investigational agent participation clinical trial within 30 day prior enrollment . Female subject pregnant lactating , include female positive pregnancy test screening must exclude . Subjects previously enrol study subsequently withdraw must also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>